Prothena Announces Appointment of Chief Regulatory Officer
December 15 2016 - 4:05PM
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE
NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage
clinical biotechnology company focused on the discovery,
development and commercialization of novel protein immunotherapies,
announced today the appointment of Carol D. Karp as Chief
Regulatory Officer. Ms. Karp will lead Prothena's Quality,
Regulatory and Safety organizations.
This new position adds important
expertise in line with Prothena's continued growth as a late-stage
clinical biotechnology company with integrated research,
development and commercial capabilities.
"Carol is a highly regarded leader
who has successfully led global regulatory, quality and safety
activities across multiple therapeutic areas and all stages of
product development," said Gene Kinney, PhD, President and Chief
Executive Officer of Prothena. "She joins Prothena as we are making
steady advances across our pipeline and continue to prepare our
commercial infrastructure in advance of key clinical data. We are
delighted to have someone with Carol's expertise join our team to
lead these key strategic activities."
Prior to joining Prothena, Ms. Karp
was an independent regulatory consultant with an extensive and
successful track record of leading global registration activities
for innovative new products in the biotechnology and pharmaceutical
sectors. Ms. Karp previously held executive leadership positions as
Senior Vice President of Regulatory Affairs and Compliance at
Esperion Therapeutics, and Vice President and Head of Global
Regulatory Affairs, Pharmacovigilance & Risk Management at
Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company,
where she led global regulatory affairs, regulatory operations and
CMC regulatory for a portfolio of neurodegenerative product
candidates. Prior to Janssen, Ms. Karp was Senior Vice President,
Regulatory Affairs, Quality Assurance and Drug Safety at CV
Therapeutics, which was acquired by Gilead Sciences. Ms. Karp also
held senior regulatory and scientific affairs positions at
PowderJect, VIVUS, Cygnus and Janssen Pharmaceutica.
Ms. Karp is a member of the Board of
Trustees at the University of Rochester, and an expert advisor and
member of the selection and review committees for the Stanford
University School of Medicine's SPARK translational research
program. Ms. Karp earned her BA in biology from the University of
Rochester.
About Prothena
Prothena Corporation plc is a global,
late-stage clinical biotechnology company seeking to fundamentally
change the course of progressive diseases with its clinical
pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein
misfolding and cell adhesion - the root causes of many serious or
currently untreatable amyloid and inflammatory diseases - Prothena
is establishing a fully integrated research, development and
commercial focus and has advanced several drug candidates into
clinical studies while pursuing discovery of additional novel
therapies. Our pipeline of antibody-based product candidates
targets a number of potential indications including AL amyloidosis
(NEOD001), Parkinson's disease and other related synucleinopathies
(PRX002), inflammatory diseases, including psoriasis and psoriatic
arthritis (PRX003), and ATTR amyloidosis (PRX004). For more
information, please visit the company's website
at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com
Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Prothena Corporation plc via Globenewswire
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2023 to Apr 2024